KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2016 - 2025)

Alnylam Pharmaceuticals' Total Non-Current Liabilities history spans 16 years, with the latest figure at $4.2 billion for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 10.31% year-over-year to $4.2 billion; the TTM value through Dec 2025 reached $4.2 billion, up 10.31%, while the annual FY2025 figure was $4.2 billion, 10.31% up from the prior year.
  • Total Non-Current Liabilities reached $4.2 billion in Q4 2025 per ALNY's latest filing, down from $4.6 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $4.6 billion in Q3 2025 to a low of $2.3 billion in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $3.5 billion, with a median of $3.6 billion recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: surged 146.4% in 2021, then grew 1.01% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $3.0 billion in 2021, then rose by 18.13% to $3.5 billion in 2022, then rose by 7.16% to $3.7 billion in 2023, then grew by 1.01% to $3.8 billion in 2024, then increased by 10.31% to $4.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Total Non-Current Liabilities are $4.2 billion (Q4 2025), $4.6 billion (Q3 2025), and $3.9 billion (Q2 2025).